FGFR2 and cholangiocarcinoma: FGFR inhibitors have generally been considered second-line treatments for CCA (with molecular assessment during or following first-line chemotherapy) [16]; however, Phase 3 studies of pemigatinib, futibatinib, and infigratinib as first-line therapies for patients harboring FGFR2 fusions or rearrangements have been attempted [32–34].